



HAL
open science

High uptake of vaccination against mpox in men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP) in Paris, France

Romain Palich, Thibaut Jedrzejewski, Luminita Schneider, Naoual Qatib, Thibault Orrière, Daniel Gosset, Thomas Grunemwald, Dominique Pataut, Michel Ohayon, Christine Katlama

► To cite this version:

Romain Palich, Thibaut Jedrzejewski, Luminita Schneider, Naoual Qatib, Thibault Orrière, et al.. High uptake of vaccination against mpox in men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP) in Paris, France. *Sexually Transmitted Infections*, 2023, pp.sextrans-2023-055885. 10.1136/sextrans-2023-055885 . hal-04191441

HAL Id: hal-04191441

<https://hal.sorbonne-universite.fr/hal-04191441>

Submitted on 30 Aug 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **ARTICLE TYPE**

2 Letter

3

4 **Title**

5 High uptake of vaccination against mpox in men who have sex with men (MSM) on HIV
6 preexposure prophylaxis (PrEP) in Paris, France

7

8 **AUTHORS**

9 Romain Palich¹, Thibaut Jedrzejewski², Luminita Schneider¹, Naoual Qatib¹, Thibault Orrière^{1,2},
10 Daniel Gosset², Thomas Grunemwald², Dominique Pataut², Michel Ohayon², Christine
11 Katlama¹

12

13 **AFFILIATIONS**

14 1. Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP,
15 Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France

16 2. "Le 190" Sexual Health Center, Paris, France

17

18 **CORRESPONDING AUTHOR**

19 Romain Palich, MD, PhD

20 Service de Maladies Infectieuses et Tropicales, hôpital Pitié-Salpêtrière, 47-83 boulevard de
21 l'hôpital, 75013 Paris, France

22 Tel: +33.1.42.16.01.71, fax: +33.1.42.16.04.45

23 Email: romain.palich@aphp.fr

24

25 **WORDS COUNT**

26 574

27

28 **KEY WORDS**

29 Mpox; vaccination; PrEP; MSM

30 **BODY TEXT**

31

32 In July 2022, the French health authorities recommended smallpox vaccination (IMVANEX® and
33 JYNNEOS®) to prevent mpox in population at high risk of exposure. HIV and PrEP physicians
34 were informed and involved in the deployment of this vaccination, but there has been no
35 communication to the general public. The current mpox epidemic in France, the rest of Europe
36 and the USA is concentrated among men who have sex with men (MSM), particularly in case
37 of multiple physical and sexual contacts [1,2]. Several case series have reported high
38 proportions of people living with HIV and of users of HIV preexposure prophylaxis (PrEP) [3,4].

39

40 To assess the uptake of vaccination among PrEP users, we conducted an observational study in
41 two centres in Paris, France (Infectious Diseases department of the Pitié-Salpêtrière hospital
42 and “Le 190” sexual health clinic). We systematically asked PrEP users who attended a routine
43 check-up for PrEP at both centres between November 2022 and January 2023 whether they
44 had received at least one vaccine dose since July 2022. We used a structured questionnaire for
45 that, administrated by the physician. If not vaccinated, we collected the reasons: prior mpox
46 disease, not feeling at risk, waiting for medical advice during their routine check-up for PrEP,
47 being against vaccination in general, or declining to answer. All information was reported in
48 medical records, and later extracted and aggregated after de-identification. According to the
49 French law (Act 78–17 of Jan 6, 1978, on Computers, Files and Liberties) this study was
50 conducted in compliance with the CNIL (French National Agency Regulating Data Protection,
51 ref. 2085881 for Pitié-Salpêtrière, and ref. 2221945 for “Le 190”), and with the reference
52 methodology 004 (www.cnil.fr).

53

54 A total of 424 MSM with a median age of 36 years (IQR 29-46) participated (Figure 1); 22 (5.2%)
55 had been previously diagnosed with mpox, and 329 (77.6%) had received at least one vaccine
56 dose. Of the remaining 73 PrEP users not yet immunised against mpox, 40 (54.8%) agreed to
57 be vaccinated. Among the 33 (45.2%) who refused, reasons given were: did not feel at risk of
58 mpox (20, 60.6%), was against vaccines in general (8, 24.2%), or preferred not to give a reason
59 (4, 12.1%). One had a formal contraindication to the vaccine (allergy). No individual who
60 received the vaccination reported severe adverse reactions.

61

62 Overall, of the 402 PrEP users who had not had a diagnosis of mpox, 369 (87.0%) have been
63 vaccinated against mpox. Interestingly, most had sought vaccination spontaneously during the
64 summer of 2022. Nearly half of PrEP users who refused vaccination did not feel at risk. This is
65 consistent with a French survey reporting that MSM on PrEP who were reluctant to be
66 vaccinated against mpox had few sex partners, and had refused other vaccinations in their
67 lifetime [5].

68

69 Our study has some limitations. We did not collect the number of vaccine doses received by
70 participants. Although it has been shown that one dose of vaccine can provide rapid protection

71 against the disease [6,7], a two-dose schedule may be required for long-term protection [8].
72 Thus, we cannot exclude that some participants may not be fully protected.

73

74 The uptake of vaccination in our study is very similar to the 89.2% reported by Canadian
75 colleagues in a recent study which included 331 transgender people and MSM [9]. Both studies
76 highlight the role that physicians can play in vaccine campaigns for the prevention of sexually
77 transmitted diseases, particularly in epidemic circumstances, by proactively offering and
78 facilitating access to vaccination.

79

80 **Acknowledgments**

81 We thank the patients, the nurses, and all the clinical staff of “Le 190” Sexual Health Center,
82 and of the Infectious Diseases department of the Pitié-Salpêtrière hospital.

83

84 **Competing interest statement**

85 No competing interest.

86

87 **Funding**


88 This study was supported by internal funding.

89

90 **Contributorship statement**

91 CK, MO and DG designed the study; RP, TJ, LS, NQ, TO, DG, TG, DP, MO and CK participated in
92 data collection, were responsible for data quality in the centers, and provided useful advice in
93 the discussion; RP wrote the first draft; all authors approved the final manuscript.

94 Figure 1. Proportions of PrEP users who were already vaccinated against mpox at the time of
95 their routine check-up for PrEP and uptake following medical recommendation to receive the
96 vaccine
97



98

99 REFERENCES

100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129

- 1 Allan-Blitz L-T, Gandhi M, Adamson P, *et al.* A Position Statement on Mpox as a Sexually Transmitted Disease. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2023;**76**:1508–12. doi:10.1093/cid/ciac960
- 2 Mitjà O, Ogoina D, Titanji BK, *et al.* Monkeypox. *Lancet Lond Engl* 2023;**401**:60–74. doi:10.1016/S0140-6736(22)02075-X
- 3 Thornhill JP, Barkati S, Walmsley S, *et al.* Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022. *N Engl J Med* 2022;:NEJMoa2207323. doi:10.1056/NEJMoa2207323
- 4 Mailhe M, Beaumont A-L, Thy M, *et al.* Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2022;:S1198-743X(22)00428-1. doi:10.1016/j.cmi.2022.08.012
- 5 Zucman D, Fourn E, Touche P, *et al.* Monkeypox Vaccine Hesitancy in French Men Having Sex with Men with PrEP or Living with HIV in France. *Vaccines* 2022;**10**:1629. doi:10.3390/vaccines10101629
- 6 Bertran M, Andrews N, Davison C, *et al.* Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. *Lancet Infect Dis* 2023;:S1473-3099(23)00057-9. doi:10.1016/S1473-3099(23)00057-9
- 7 Wolff Sagy Y, Zucker R, Hammerman A, *et al.* Real-world effectiveness of a single dose of mpox vaccine in males. *Nat Med* 2023;**29**:748–52. doi:10.1038/s41591-023-02229-3
- 8 Payne AB, Ray LC, Cole MM, *et al.* Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons- 43 U.S. Jurisdictions, July 31-October 1, 2022. *MMWR Morb Mortal Wkly Rep* 2022;**71**:1560–4. doi:10.15585/mmwr.mm7149a5
- 9 Gilbert M, Ablona A, Chang H-J, *et al.* Uptake of Mpox vaccination among transgender people and gay, bisexual and other men who have sex with men among sexually-transmitted infection clinic clients in Vancouver, British Columbia. *Vaccine* 2023;**41**:2485–94. doi:10.1016/j.vaccine.2023.02.075